Inhaled thiamphenicol and acetylcysteine in children with acute bacterial rhinopharyngitis.
Antibiotic abuse for treating rhinopharyngitis induces the occurrence of resistant bacteria. As topical drugs might reduce this phenomenon, the aims of our study are to evaluate inhaled thiamphenicol associated with acetylcysteine in children with acute bacterial rhinopharyngitis and to compare it with the use of saline solution. The trial was conducted as randomized, parallel group, and single blind. Children, aged 3-6 years, with acute bacterial rhinopharyngitis were treated with aerosolized thiamphenicol associated with acetylcysteine (250 mg: 1/2 vial in the morning and 1/2 vial in the evening) (Group A) or saline solution twice daily (Group B), both of them for 5 days. Both treatments were administered using a new device: Rinowash. The following parameters were assessed: nasal obstruction, mucopurulent rhinorrhea, post-nasal drip, cough, sore throat, fever, and cultures. Of 104 patients screened, 90 children, median age 3.7 years (44 females and 46 males), completed the study: 60 in Group A and 30 in Group B. Actively-treated children achieved a significant improvement of all parameters, but fewer than the control group. In conclusion, inhaled thiamphenicol associated with acetylcysteine may represent a valid treatment for acute bacterial rhinopharyngitis in children, as it is effective, safe, economic, and simple to use.
Varricchio
A
A
ENT Unit, San Gennaro Hospital, Naples, Italy.
Capasso
M
M
Di Gioacchino
M
M
Ciprandi
G
G
D000111:Acetylcysteine / Q000008:administration & dosage*; D000208:Acute Disease; D000280:Administration, Inhalation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy*; D012220:Rhinitis / Q000188:drug therapy*; D016037:Single-Blind Method; D013839:Thiamphenicol / Q000008:administration & dosage*
D013839:Thiamphenicol; D000111:Acetylcysteine